טוען...
Darbepoetin as a Neuroprotective Agent in Mild Neonatal Encephalopathy: A Randomized, Placebo Controlled, Feasibility Trial
OBJECTIVE: To assess the feasibility and safety of one dose of Darbepoetin alpha (Darbe) administered to neonates ≥34 weeks with mild neonatal encephalopathy (NE) METHODS: Randomized, masked, placebo-controlled study including neonates ≥34 weeks gestation with mild NE. Neonates were randomized to re...
שמור ב:
| הוצא לאור ב: | J Perinatol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8238874/ https://ncbi.nlm.nih.gov/pubmed/33986477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41372-021-01081-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|